Antibody Drug Conjugates Market (2nd Edition), 2014 - 2024

News provided by

23 Sep, 2014, 18:16 BST

DUBLIN, Sept. 23, 2014 /PRNewswire/ -- Research and Markets has announced the addition of the "Antibody Drug Conjugates Market (2nd Edition), 2014 - 2024" report to their offering.

http://photos.prnewswire.com/prnh/20130307/600769

Research and Markets Logo. (PRNewsFoto/PR NEWSWIRE EUROPE)

Antibody drug conjugates (ADCs) are a new class of therapeutic agents, gaining increasing attention from both large and small pharmaceutical companies. Generally addressed as the marriage of an antibody with a toxic drug / chemotherapy drug, these conjugates are believed to be more efficient and effective in the treatment of a disease.

The ADC market is still in its infancy. At present, Adcetris and Kadcyla are the only two marketed drugs. However, there are several ADCs under development, with most of them being developed for oncological indication. Pharmaceutical companies are keen to add innovative molecules to their diminishing product pipelines and ADCs provide an attractive opportunity due to their novel nature.

Although the market now has presence of several large pharmaceutical companies, the technological capabilities for development of ADC still lies with a few technology providers. Seattle Genetics and ImmunoGen are amongst the pioneers in the field of ADC, with most pipeline ADCs using their technology. Most development to date has been carried under technology license agreements. However, we expect to see more co-development agreements in the future.

As more ADCs move from pipeline to the market, there is likely to be a further increase in investments in this area. Drug developers / venture capital firms are investing huge amount of money in biologics and it remains to be seen what proportion of this will be directed towards ADCs. The current market landscape will gradually evolve as large pharmaceutical companies look to gain competitive advantage in the ADC market. The future of the market is promising, though there are several challenges to meet.

The Antibody Drug Conjugates Market (2nd edition), 2014-2024 report provides an extensive study on this emerging field of therapeutics. The report covers various aspects, such as, advantages of antibody drug conjugates over traditional antibody therapeutics, the need for this new class of medicine, manufacturing challenges, key market drivers and upcoming opportunities.

One of the key objectives of this report is to understand the current and future state of the antibody drug conjugates market. This is done by analyzing:

Products currently available in the market and those under development (both clinical / pre-clinical),
Technology providers, and key cytotoxin, linker and conjugation technologies supporting the development of improved ADCs,
Partnerships which have taken place over the last five years covering product co-development, technology licensing and co-marketing,
Competitive landscape and inherent threats to growth in the short and long term,
Development and sales potential based on target consumer segments, likely adoption rate and expected pricing.

Key Topics Covered:

1. PREFACE

2. EXECUTIVE SUMMARY

3. INTRODUCTION

4. ADC THERAPEUTICS: OVERVIEW AND BACKGROUND

5. ADC MARKET FORECAST, 2014 - 2024

6. MANUFACTURING OF ADCs

7. RECENT DEVELOPMENTS: FOCUS ON PARTNERSHIPS AND TECHNOLOGY EVOLUTION

8. PROFILES OF LEADING COMPANIES

9. SWOT ANALYSIS

10. INTERVIEW TRANSCRIPTS

11. CONCLUSIONS

12. APPENDIX 1: TABLES

13. APPENDIX 2: LIST OF COMPANIES AND ORGANISATIONS

Companies Mentioned:

5AM Ventures
Abbott
AbbVie
Abgenix
AbGenomics
Abzena
Acceleris Capital
ADC Biotechnology
ADC Therapeutics
Adimab
Affinicon
Agensys
Albany Molecular Research, Inc. (AMRI)
Allozyne
Alpha Cancer Technologies
Alta Partners
Ambrx
Amerisource Bergen Corporation
Amgen
Amgen Ventures
Antitope
Apposite Capital
Aravis General Partner
Astellas Pharma
AstraZeneca
Avid Biologics
Baxter BioPharma Solutions
Bayer Healthcare
biOasis Technologies
Biocon
BioInvent International
Biotecnol
Biotest
BioXpress Therapeutics
Boehringer Ingelheim
Bristol-Myers Squibb
BSP Pharmaceuticals
Cambrex Corporation
Cape Family Fund LLC
Carbogen Amcis
Cardinal Health, Inc
Catalent Pharma Solutions
Celldex Therapeutics
Celltrion
Celtic Therapeutics Holdings
Chugai Pharmaceuticals
CMEA Capital
CuraGen
CytomX Therapeutics
Cytovance Biologics LLC
Daiichi Sankyo
Dendreon Corporation
Dong-A Pharmaceutical
DSM Pharmaceuticals
Eli Lilly
Endo Pharmaceuticals
Endocyte
Esperance Pharmaceuticals
Fidelity Biosciences
Fujifilm Diosynth Biotechnologies
Genentech
Genmab
Glycotope
Goodwin Biotechnology
GSK
Hanwha Chemical
Harris and Harris Group
Heidelberg Pharma
Igenica
ImmunoGen
Immunomedics
Intellect Neurosciences
ISU Abxis
Janssen Cilag
Johnson & Johnson
Lansing Brown Investments LLC
Laureate Biopharmaceutical Services
Lilly Ventures
Lonza
MacroGenics
Maverick Capital
McKesson Corporation
Medarex
MedImmune
Medivation
Meiji Seika Pharma
Menarini Group
Merck
Merck KGaA
Mersana Therapeutics
Micromet
Millennium
Mylan
NBE Therapeutics
New Enterprise Associates
Nippon Kayaku
Novartis
Novasep
Oxford BioTherapeutics
Pfizer
Pfizer Venture Investments
Philochem
PhotoBiotics
Pierre Fabre Medicament Production
Piramal Healthcare Pharma Solutions
PlantForm Corporation
Polytherics
Progenics Pharmaceuticals
ProQuest Investments
PureTech Ventures
Redwood Bioscience
Rho Ventures
Roche
Sanofi Aventis
Seattle Genetics
Shanghai CP Guojian
Sigma Aldrich Fine Chemicals (SAFC)
Skyline Ventures
SocietàItalianaCorticosteroidiS.r.l
Spirogen
Stem CentRx
Sumitomo Pharmaceuticals
Sutro Biopharma
SV Life Sciences
SynAffix
Synthon
Takeda Pharmaceuticals
Tavistock Life Sciences
ThioLogics
TUBE Pharma
UCB Pharma
Ventana Medical Systems
Versant Ventures
VIVENTIA Biotechnologies
Watson Pharmaceuticals
Wilex
Wyeth
Zhejiang Medicine Co. Ltd. (ZMC)

For more information visit http://www.researchandmarkets.com/research/6vc6gm/antibody_drug

Media Contact: Laura Wood, +353-1-481-1716, press@researchandmarkets.net

SOURCE Research and Markets